Lung Cancer
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy assay while Personalis completes its clinical validation in more indications.
Cannabis Use Disorders Linked to Population-Specific Risk Loci in GWAS Meta-Analysis
Researchers flagged cannabis use disorder-associated loci in African, East Asian, European, and admixed American populations before digging into related traits and behaviors.
Foundation Medicine, Pierre Fabre Laboratories to Collaborate on CDx for Lung Cancer
The companies will seek approval for Foundation Medicine's assays identifying patients for treatment with Pierre Fabre's BRAF/MEK inhibitor combination regimen.
Following a recent leadership change, glycoproteomics firm InterVenn Biosciences is reevaluating its commercial strategy and direction.
FDA Approves Foundation Medicine CDx Tests for Pfizer's Braftovi-Mektovi Combo in Lung Cancer
The FoundationOne CDx and FoundationOne Liquid CDx tests were approved to determine whether patients with metastatic non-small cell lung cancer may be eligible for treatment.